Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) AI Stock Analysis

• Market Cap: HK$640.17M
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): <0.01
• Revenue Growth: -5.79%
• EPS Growth: -129.73%
• Country: HK
• Employees: 260
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): N/A
• Shares Outstanding: 1,436,400,000
• 10 Day Avg. Volume: 2,135,000
• 30 Day Avg. Volume: 1,681,333
• PEG Ratio: -0.19
• Price to Book (P/B): 24.48
• Price to Sales (P/S): 1.41
• P/FCF Ratio: -18.81
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: HK$0.29 ▼(-26.50% Downside)

The overall stock score is heavily influenced by the company's poor financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. The absence of earnings call data and corporate events leaves the financial and technical analysis as the primary factors in the score.

Positive Factors

Diverse Revenue Streams

The company's diverse revenue streams, including medical devices, biopharmaceuticals, and partnerships, provide a robust foundation for long-term growth and resilience against market fluctuations.

Government Contracts

Government contracts and funding enhance financial stability and market presence, providing a reliable revenue source and potential for expansion in the healthcare sector.

Commitment to Innovation

A strong focus on innovation in medical technology positions the company to capitalize on industry advancements and improve patient outcomes, driving long-term competitive advantage.

Negative Factors

High Leverage

The significant increase in leverage indicates a heavy reliance on debt financing, which poses financial risks and limits the company's flexibility in managing economic downturns.

Negative Cash Flows

Persistent negative cash flows highlight challenges in liquidity management and cash generation, potentially hindering the company's ability to invest in growth opportunities.

Declining Revenue

The declining revenue trend suggests weakening market position and demand for products, which could impact long-term profitability and necessitate strategic changes.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) is a leading Chinese company focused on the development, production, and sales of advanced biomedical engineering products. The company operates primarily in the healthcare sector, specializing in medical devices, biopharmaceuticals, and innovative healthcare solutions. With a commitment to enhancing patient outcomes and advancing medical technology, TEDA Biomedical Engineering offers a range of products including diagnostic equipment, therapeutic devices, and bio-materials.

How the Company Makes Money

Tianjin TEDA Biomedical Engineering generates revenue through multiple streams including the sale of medical devices and biopharmaceutical products to hospitals, clinics, and healthcare providers. Additionally, the company may engage in research and development partnerships with other firms and institutions, allowing it to innovate and expand its product offerings. The revenue model is further supported by government contracts and funding for healthcare projects, as well as collaborations with healthcare organizations aimed at improving medical technology. These partnerships can provide significant financial backing and enhance the company's market presence.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview

Summary

The company is experiencing significant financial challenges, with declining revenue, persistent net losses, high leverage, and negative cash flows. These factors indicate critical financial instability and a need for strategic restructuring.

Income Statement

The income statement reveals a declining trend in revenue, with Total Revenue decreasing from 476 million in 2021 to 385 million in 2024. Gross Profit Margin has narrowed significantly, and the company has been consistently incurring net losses, with a Net Income of -27.8 million in 2024. The EBIT and EBITDA margins are negative, indicating operational inefficiencies and challenges in maintaining profitability.

Balance Sheet

The balance sheet shows a weak financial structure with a high Debt-to-Equity ratio, increasing from 0.38 in 2019 to 7.22 in 2024, indicating heavy reliance on debt financing. Stockholders' Equity has diminished substantially, impacting the Equity Ratio, which fell to 6.66% in 2024. The company’s high leverage poses significant financial risk.

Cash Flow

Cash flow analysis points to severe issues, with Operating Cash Flow consistently negative, signaling poor cash generation ability. Free Cash Flow has been negative over multiple years, showing challenges in maintaining liquidity. The lack of positive cash flow ratios suggests difficulties in converting profits into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	226.41M	385.48M	398.00M	403.73M	476.38M	369.36M
Gross Profit	13.82M	16.97M	21.37M	14.82M	45.60M	40.39M
EBITDA	-3.20M	-20.19M	4.79M	-2.26M	-29.86M	-21.52M
Net Income	-6.43M	-27.80M	-20.16M	-27.45M	-42.26M	-48.00M
Balance Sheet
Total Assets	415.16M	332.53M	303.28M	337.20M	347.60M	392.92M
Cash, Cash Equivalents and Short-Term Investments	186.13M	25.40M	5.93M	9.55M	29.78M	35.53M
Total Debt	112.58M	159.92M	83.56M	102.61M	90.34M	54.65M
Total Liabilities	314.26M	304.09M	238.70M	253.48M	237.24M	237.77M
Stockholders Equity	96.62M	22.15M	49.95M	70.11M	100.78M	143.04M
Cash Flow
Free Cash Flow	-99.23M	-28.83M	-15.62M	-21.62M	-40.38M	21.96M
Operating Cash Flow	-98.40M	-26.27M	-13.15M	-12.82M	-6.68M	35.99M
Investing Cash Flow	6.72M	-37.24M	-467.44K	-12.93M	-8.51M	-26.51M
Financing Cash Flow	78.55M	82.95M	12.73M	6.17M	28.10M	-20.19M

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.39, and below the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 17.82 is Positive, neither overbought nor oversold. The STOCH value of 32.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8189.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1866	76 Outperform	HK$10.10B	6.46	15.41%	3.01%	0.82%	2.99%
0297	71 Outperform	$10.68B	8.91	10.34%	3.52%	-0.34%	64.10%
3983	69 Neutral	$11.29B	10.22	5.60%	5.20%	-8.24%	-24.53%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
0827	46 Neutral	HK$162.76M	-0.27	-112.79%	―	-22.72%	-212.73%
8189	37 Underperform	HK$640.17M	―	-44.61%	―	-5.79%	-129.73%